TranStar102: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 30, 2026 - P1/2 | N=320 | Active, not recruiting | Sponsor: Transcenta Therapeutics (Hangzhou) Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2026 ➔ Sep 2027 | Trial primary completion date: Jun 2026 ➔ Jun 2027
Enrollment closed • Trial completion date • Trial primary completion date • Biliary Tract Cancer • Colorectal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CLDN18 • HER-2
|